At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,842 enrolled
Drug / intervention
Dulaglutidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients With Type 2 Diabetes Mellitus
In Brief
A Phase 3 clinical trial evaluating Dulaglutide for Diabetes Mellitus, Type 2. Completed, enrolled 1,842 participants across 208 sites in 16 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of investigational doses of once weekly dulaglutide when added to metformin in participants with type 2 diabetes with inadequate blood sugar control.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesArgentina, Austria, Canada, Greece, Hungary, Israel, Italy, Mexico, Poland, Puerto Rico, Romania, Russia, Slovakia, Spain, Taiwan, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
Enrollment StartApr 2018
First PostedApr 2018
Primary CompletionMay 2019
Study CompletionOct 2019
TodayJul 2026
First PostedApr 11, 2018
Enrollment StartApr 5, 2018
Primary CompletionMay 28, 2019
Study CompletionOct 10, 2019
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 8.2 years ago
Interventions
Dulaglutidedrug
Administered SC